
StockWatch: Sarepta Says Deaths of Two Elevidys Patients Posted on FDA Database Unrelated to Treatment
Sarepta Therapeutics (NASDAQ: SRPT) said Friday that the deaths of two patients taking its marketed gene therapy Elevidys® (delandistrogene moxeparvovec-rokl), posted on a public FDA database and reported this past week in an analyst’s research note, were …